UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
__________________________________________________
Filed by the Registrant ☒  Filed by a Party other than the Registrant  ☐
Check the appropriate box:
☐
Preliminary Proxy Statement
☐
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐
Definitive Proxy Statement
☒
Definitive Additional Materials
☐
Soliciting Material under §240.14a-12
AURINIA PHARMACEUTICALS INC.
(Name of Registrant as Specified In Its Charter)
 
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
☒
No fee required.
☐
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)
Title of each class of securities to which transaction applies:
  
(2)
Aggregate number of securities to which transaction applies:
  
(3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
  
(4)
Proposed maximum aggregate value of transaction:
  
(5)
Total fee paid:
  
☐
Fee paid previously with preliminary materials.
☐
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)
Amount Previously Paid:
  
(2)
Form, Schedule or Registration Statement No.:
  
(3)
Filing Party:
  
(4)
Date Filed:
 

 
Vote Virtually at the Meeting* June 14, 2024 12:00 PM EDT Virtually at: web.lumiagm.com/415837864 Password: aurinia2024 *Please check the meeting materials for any special requirements for meeting attendance. Please review the meeting materials before voting. Smartphone users Point your camera here and vote without entering a control number Your Vote Counts! AURINIA PHARMACEUTICALS INC. 2024 Annual General Meeting Vote by June 12, 2024 12:00 PM ET For complete information and to vote, visit www.ProxyVote.com Control # V51335-P13968 You invested in AURINIA PHARMACEUTICALS INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual General Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 14, 2024. Get informed before you vote View the Notice, Proxy Statement, Financial Statement request form and Annual Report online at www.sec.gov, www.sedarplus.ca or https://ir.auriniapharma.com OR you can receive a free paper or email copy of the material(s) by requesting prior to May 31, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

 
AURINIA PHARMACEUTICALS INC. 2024 Annual General Meeting Vote by June 12, 2024 12:00 PM ET THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com V51336-P13968 Voting Items Board Recommends 1. Election of Directors Nominees: 1a. Peter Greenleaf For 1b. Dr. David R. W. Jayne For 1c. Dr. Daniel G. Billen For 1d. R. Hector MacKay-Dunn For 1e. Jill Leversage For 1f. Dr. Brinda Balakrishnan For 1g. Dr. Karen Smith For 1h. Jeffrey A. Bailey For 1i. Dr. Robert T. Foster For 2. To appoint PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm until the close of the 2025 annual general meeting of shareholders or until a successor is appointed. For 3. To approve, on a non-binding advisory basis, a “say on pay” resolution regarding the Company’s executive compensation set forth in the Company’s Proxy Statement/Circular. For 4. To approve the amendment to the Company’s Equity Incentive Plan to increase the maximum number of common shares of the Company reserved for issuance pursuant to the Equity Incentive Plan, as set forth in the Company’s Proxy Statement/Circular. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.